Be the first to like this
Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct
acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy.
Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and
neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper
provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions
(DDIs) between DAAs and psychiatric medications.